MA-EDB
2.11.2021 13:02:12 CET | Business Wire | Press release
EDB , a leading contributor to PostgreSQL®, today announced the general availability of its BigAnimal™ offering, the first fully-managed PostgreSQL database in the cloud with compatibility for Oracle database technology. Built and backed by the world’s largest roster of PostgreSQL engineers, BigAnimal is for enterprises looking to deploy their most demanding databases into the cloud.
“BigAnimal was built in direct response to what our customers told us was missing from existing cloud Postgres offerings,” said EDB president and CEO, Ed Boyajian. “These improvements aren’t incremental - they’re transformational. We’ve made no compromises. This means you get fanatical attention from the biggest team in Postgres, native compatibility with Oracle database technology, and extreme high availability. And we run it all inside your cloud account.”
Accelerate Business with the Best Cloud PostgreSQL
Customers who are building serious cloud applications are realizing that they can’t get what they need from the basic PostgreSQL offerings available today. Without the transparency, control, and performance tuning required for their most demanding workloads, they are held back from moving fully into the cloud. BigAnimal responds to these needs by giving organizations granular control over the database within their own accounts and all the enterprise PostgreSQL capabilities EDB has been developing over the past 15 years - while being fully managed by EDB.
Specifically, with BigAnimal, enterprises will experience the following benefits:
- Partner with PostgreSQL builders . For over a decade, PostgreSQL users have counted on EDB for their on-premises deployments. Now with BigAnimal, users can also rely on unequaled support from EDB’s world-class PostgreSQL experts.
- Migrate applications on Oracle databases to PostgreSQL on Azure with little to no changes needed. With BigAnimal, customers can reduce costs, time, and risks when migrating workloads from legacy Oracle databases to cloud environments. BigAnimal’s deep compatibility with Oracle database technology and comprehensive migration tools address a critical need for enterprises who want to move quickly without leaving behind all their legacy database investments in code, skill sets, and resources.
- Increase transparency and control of their cloud PostgreSQL . BigAnimal runs in a customer’s cloud account, allowing them to closely manage, secure, and optimize their PostgreSQL along with their other infrastructure according to their business needs and spend commitments. BigAnimal also gives users an unprecedented level of control over their PostgreSQL with superuser access to precisely tweak database internals.
- Minimize complexity with the same PostgreSQL everywhere. EDB Postgres users can expect a uniform database experience, from EDB Postgres on premises to BigAnimal on Azure. This includes the ability to use their existing PostgreSQL skill sets, incorporate the database into their DevOps pipelines, and leverage EDB Postgres Advanced enterprise capabilities, such as enhanced security, performance management, and compatibility with Oracle database technology. With support for license portability, EDB also allows customers to easily deploy PostgreSQL whenever, wherever their business requires.
According to Carl Olofson, research vice president, Data Management Software, IDC: “In 2021, we saw a significant rise in cloud infrastructure spend and expect it to soon surpass non-cloud infrastructure. With this growing reliance on cloud platforms, many companies don’t have the in-house skills to deploy, manage, and optimize their databases. Considering EDB’s long track record of building and supporting Postgres, companies have a strong option for transitioning smoothly and optimizing their cloud database operations.”
For more information about EDB and BigAnimal and to sign up for a trial, please visit www.biganimal.com .
EnterpriseDB, EDB and Postgres Enterprise Manager are registered trademarks of EnterpriseDB Corporation. EDB Postgres and BigAnimal are trademarks of EnterpriseDB Corporation.
Postgres, PostgreSQL, and the Slonik Logo are trademarks or registered trademarks of the PostgreSQL Community Association of Canada, and used with their permission.
About EDB
PostgreSQL is increasingly the database of choice for organizations looking to boost innovation and accelerate business. EDB’s enterprise-class software extends PostgreSQL, helping our customers get the most out of it both on premises and in the cloud. And our 24x7 global support, professional services, and training help our customers control risk, manage costs, and scale efficiently. With 16 offices worldwide, EDB serves over 5,000 customers, including leading financial services, government, media and communications, and information technology organizations. To learn about PostgreSQL for people, teams, and enterprises, visit EDBpostgres.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AIT Worldwide Logistics Welcomes Justin Kosslyn as Chief Digital and Technology Officer13.7.2026 17:02:00 CEST | Press release
Proven leader with Google experience to advance company’s AI-powered digital transformation Supply chain solutions leader AIT Worldwide Logistics has hired Justin Kosslyn, a tenured software development executive, as its chief digital and technology officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713269550/en/ Justin Kosslyn will lead an accelerating digital transformation at AIT Worldwide Logistics, unifying a vastly diverse array of shippers and partners across the globe. In the newly created role, Kosslyn will report directly to President and Chief Operating Officer, Keith Tholan, and lead the company’s global technology strategy, continuing to implement AIT’s existing program while accelerating the next generation of integrated digital, data, AI and customer-facing systems across the organization. “With a history of delivering for companies at the center of global technology and innovation, Justin brings the k
Labaton Keller Sucharow LLP Launches Corporate Accountability & Governance Task Force13.7.2026 16:46:00 CEST | Press release
Labaton Keller Sucharow LLP is pleased to announce the launch of its new Corporate Accountability & Governance Task Force, designed to help institutional investors advance corporate accountability while pursuing meaningful shareholder recoveries. Created in response to the increasing needs of our clients, the Task Force will provide clients with strategic advice on opportunities to drive positive corporate change through securities and shareholder litigation. This initiative reflects the Firm’s longstanding commitment to protecting investor interests while promoting responsible corporate conduct. Labaton partners with institutional investor clients to pursue cases that not only seek financial recovery but also encourage meaningful corporate reforms and reinforce sound governance practices. The Task Force is chaired by Partners Carol C. Villegas and Domenico “Nico” Minerva, who have led some of the Firm's most significant matters involving corporate accountability and governance reform.
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release
The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio
Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release
Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
